← Back to All US Stocks

NutriBand Inc. (NTRBW) Stock Fundamental Analysis & AI Rating 2026

NTRBW Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies NV CIK: 0001676047
Updated This Month • Analysis: Apr 3, 2026 • SEC Data: 2025-10-31
Combined AI Rating
SELL
84% Confidence
AGREEMENT
STRONG SELL
95% Conf
SELL
73% Conf

📊 NTRBW Key Takeaways

Revenue: $1.6M
Net Margin: -443.9%
Free Cash Flow: $-4.4M
Current Ratio: 7.53x
Debt/Equity: 0.00x
EPS: $-2.54
AI Rating: STRONG SELL with 95% confidence
NutriBand Inc. (NTRBW) receives a SELL rating with 84% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $1.6M, net profit margin of -443.9%, and return on equity (ROE) of -96.2%, NutriBand Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete NTRBW stock analysis for 2026.

Is NutriBand Inc. (NTRBW) a Good Investment?

Claude

NutriBand Inc. is a fundamentally distressed company burning cash at an unsustainable rate with minimal revenue generation. Despite holding $5.3M in cash, operating losses of $7.3M per period combined with negative operating cash flow of $4.4M indicate the company is rapidly consuming its liquidity cushion with no clear path to profitability.

ChatGPT

Fundamentals show a tiny, flat revenue base, sub-30% gross margin, and extremely negative operating and net margins driving heavy cash burn and deeply negative ROE/ROA. While the balance sheet is clean with strong liquidity, ample cash, and negligible debt, current operating cash outflows imply a limited runway without rapid revenue scaling or margin improvement. Absent clear progress on commercialization and cost discipline, dilution and continued losses are likely.

Why Buy NutriBand Inc. Stock? NTRBW Key Strengths

Claude
  • + Strong liquidity position with $5.3M cash representing 63% of total assets
  • + Minimal debt burden with only $1.8K long-term debt and 0.00x debt-to-equity ratio
  • + Low current liabilities relative to liquid assets providing short-term solvency
ChatGPT
  • + Net cash position with minimal liabilities and no leverage
  • + Strong liquidity (current 7.5x, quick 7.35x) supports near‑term obligations
  • + Low capex needs indicate an asset‑light model

NTRBW Stock Risks: NutriBand Inc. Investment Risks

Claude
  • ! Severe operating losses of $7.3M against $1.6M revenue, indicating fundamental business model failure
  • ! Negative operating cash flow of $4.4M per period means company will deplete cash reserves in approximately 1.2 periods at current burn rate
  • ! Revenue stagnation with 0.0% YoY growth while operating expenses remain massive, showing no operational leverage or path to scaling
  • ! Negative ROE of -96.2% and ROA of -86.3% demonstrate value destruction across all invested capital
  • ! Operating margin of -446% and net margin of -443.9% indicate the company loses $4.46 for every dollar of revenue
ChatGPT
  • ! Persistent operating losses and negative FCF (-$4.41M) with -446% operating margin
  • ! Flat revenue and weak gross margin (29.2%) suggest limited operating leverage
  • ! Potential equity dilution to fund operations as cash runway compresses

Key Metrics to Watch

Claude
  • * Quarterly cash position and runway remaining at current burn rate
  • * Revenue trends and new product launch success in orthopedic appliances sector
  • * Operating expense reduction initiatives and path to operating cash flow positivity
ChatGPT
  • * Quarterly revenue growth and gross margin trajectory
  • * Operating cash burn versus cash balance (runway)

NutriBand Inc. (NTRBW) Financial Metrics & Key Ratios

Revenue
$1.6M
Net Income
$-7.3M
EPS (Diluted)
$-2.54
Free Cash Flow
$-4.4M
Total Assets
$8.4M
Cash Position
$5.3M

💡 AI Analyst Insight

Strong liquidity with a 7.53x current ratio provides a solid financial cushion.

NTRBW Profit Margin, ROE & Profitability Analysis

Gross Margin 29.2%
Operating Margin -446.0%
Net Margin -443.9%
ROE -96.2%
ROA -86.3%
FCF Margin -269.5%

NTRBW vs Healthcare Sector: How NutriBand Inc. Compares

How NutriBand Inc. compares to Healthcare sector averages

Net Margin
NTRBW -443.9%
vs
Sector Avg 12.0%
NTRBW Sector
ROE
NTRBW -96.2%
vs
Sector Avg 15.0%
NTRBW Sector
Current Ratio
NTRBW 7.5x
vs
Sector Avg 2.0x
NTRBW Sector
Debt/Equity
NTRBW 0.0x
vs
Sector Avg 0.6x
NTRBW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is NutriBand Inc. Stock Overvalued? NTRBW Valuation Analysis 2026

Based on fundamental analysis, NutriBand Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-96.2%
Sector avg: 15%
Net Profit Margin
-443.9%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

NutriBand Inc. Balance Sheet: NTRBW Debt, Cash & Liquidity

Current Ratio
7.53x
Quick Ratio
7.35x
Debt/Equity
0.00x
Debt/Assets
10.3%
Interest Coverage
-424.22x
Long-term Debt
$1.8K

NTRBW Revenue & Earnings Growth: 5-Year Financial Trend

NTRBW 5-year financial data: Year 2022: Revenue $1.2M, Net Income -$2.9M, EPS N/A. Year 2023: Revenue $1.8M, Net Income -$6.2M, EPS $-0.80. Year 2024: Revenue $2.1M, Net Income -$4.5M, EPS $-0.53. Year 2025: Revenue $2.1M, Net Income -$5.5M, EPS $-0.69.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: NutriBand Inc.'s revenue has grown significantly by 81% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.69 indicates the company is currently unprofitable.

NTRBW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-269.5%
Free cash flow / Revenue

NTRBW Quarterly Earnings & Performance

Quarterly financial performance data for NutriBand Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2026 $346.1K -$1.4M $-0.12
Q2 2026 $442.8K -$1.7M $-0.15
Q1 2026 $408.5K -$1.4M $-0.12
Q3 2025 $427.8K -$1.4M $-0.12
Q1 2025 $408.5K -$1.0M $-0.13
Q3 2024 $427.8K -$1.1M $-0.14
Q2 2024 $442.8K -$829.2K $-0.11
Q2 2023 $456.1K -$829.2K $-0.11

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

NutriBand Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$4.4M
Cash generated from operations
Capital Expenditures
$5.3K
Investment in assets
Dividends
None
No dividend program

NTRBW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for NutriBand Inc. (CIK: 0001676047)

📋 Recent SEC Filings

Date Form Document Action
Apr 7, 2026 8-K ea0285330-8k_nutriband.htm View →
Feb 13, 2026 8-K ea0277156-8k_nutriband.htm View →
Feb 3, 2026 8-K ea0275277-8k_nutriband.htm View →
Dec 30, 2025 8-K ea0271298-8k_nutriband.htm View →
Dec 19, 2025 DEF 14A ea0267930-01.htm View →

Frequently Asked Questions about NTRBW

What is the AI rating for NTRBW?

NutriBand Inc. (NTRBW) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are NTRBW's key strengths?

Claude: Strong liquidity position with $5.3M cash representing 63% of total assets. Minimal debt burden with only $1.8K long-term debt and 0.00x debt-to-equity ratio. ChatGPT: Net cash position with minimal liabilities and no leverage. Strong liquidity (current 7.5x, quick 7.35x) supports near‑term obligations.

What are the risks of investing in NTRBW?

Claude: Severe operating losses of $7.3M against $1.6M revenue, indicating fundamental business model failure. Negative operating cash flow of $4.4M per period means company will deplete cash reserves in approximately 1.2 periods at current burn rate. ChatGPT: Persistent operating losses and negative FCF (-$4.41M) with -446% operating margin. Flat revenue and weak gross margin (29.2%) suggest limited operating leverage.

What is NTRBW's revenue and growth?

NutriBand Inc. reported revenue of $1.6M.

Does NTRBW pay dividends?

NutriBand Inc. does not currently pay dividends.

Where can I find NTRBW SEC filings?

Official SEC filings for NutriBand Inc. (CIK: 0001676047) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is NTRBW's EPS?

NutriBand Inc. has a diluted EPS of $-2.54.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is NTRBW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, NutriBand Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is NTRBW stock overvalued or undervalued?

Valuation metrics for NTRBW: ROE of -96.2% (sector avg: 15%), net margin of -443.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy NTRBW stock in 2026?

Our dual AI analysis gives NutriBand Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is NTRBW's free cash flow?

NutriBand Inc.'s operating cash flow is $-4.4M, with capital expenditures of $5.3K. FCF margin is -269.5%.

How does NTRBW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -443.9% (avg: 12%), ROE -96.2% (avg: 15%), current ratio 7.53 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 3, 2026 | Data as of: 2025-10-31 | Powered by Claude AI